中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.032 seconds)

    RECEPTOR FUNCTION ASSAYS
    1.
    发明申请
    RECEPTOR FUNCTION ASSAYS 审中-公开
    受体功能测定

    公开(公告)号：WO1995004136A1

    公开(公告)日：1995-02-09

    申请号：PCT/US1994008571

    申请日：1994-07-29

    Applicant: COR THERAPEUTICS, INC. ,  GIESE, Neill, A.

    Inventor： COR THERAPEUTICS, INC.

    IPC: C12N09/12

    CPC classification number: G01N33/5008 ,  G01N2333/9121

    Abstract: Methods are provided for assaying the function (e.g., activation) of signal-transducing receptors on cells. The methods are useful for identifying compounds that are agonists or antagonists of receptor function. The assays utilize a two-antibody sandwich assay employing an immobilized first antibody that specifically binds and captures the receptor of interest along with any tightly associated proteins or polypeptides and a second antibody directed against (i) an epitope of the receptor that is characteristic of the activated but not the unactivated state, (ii) an epitope of a protein or molecule characteristically bound to activated receptor but not to unactivated receptor, or (iii) an epitope of the receptor that is characteristic of the unactivated but not the activated state. In one embodiment, the level of binding of the second antibody is determined and correlated with the presence of activated receptor, and thus with activation in response to the treatment received by the cells. The methods provided by the invention will find particular use for detecting activation of tyrosine kinase growth factor receptors.

    Abstract translation: 提供了用于测定细胞上信号转导受体的功能（例如激活）的方法。 该方法可用于鉴定作为受体功能的激动剂或拮抗剂的化合物。 该测定法利用采用固定化的第一抗体的双抗体夹心测定法，其特异性结合并捕获感兴趣的受体以及任何紧密相关的蛋白质或多肽，以及针对（i）受体表位的第二抗体，其特征在于 活化但不是未活化状态，（ii）特征性结合活化受体但不结合未活化受体的蛋白质或分子的表位，或（iii）受体的表位，其是未活化但不是活化状态的特征。 在一个实施方案中，确定第二抗体的结合水平并与活化受体的存在相关，并因此响应于由细胞接受的治疗而激活。 本发明提供的方法将特别用于检测酪氨酸激酶生长因子受体的活化。

    MODULATION OF INTEGRIN-MEDIATED SIGNAL TRANSDUCTION
    2.
    发明申请
    MODULATION OF INTEGRIN-MEDIATED SIGNAL TRANSDUCTION 审中-公开
    整合信号传输的调制

    公开(公告)号：WO1997014432A1

    公开(公告)日：1997-04-24

    申请号：PCT/US1996016790

    申请日：1996-10-18

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  PHILIPS, David ,  LAW, Debbie, A. ,  ALAIMO, Lisa, N.

    IPC: A61K39/00

    CPC classification number: C07K14/70546

    Abstract: The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the beta -subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin mediated signaling, methods of identifying agents which block integrin mediated signaling, methods of using agents which block intergrin mediated signaling to modulate biological and pathological processes, and agents which block integrin mediated signaling.

    Abstract translation: 本发明公开了信号蛋白结合所需的β亚单位的胞质酪氨酸残基的磷酸化。 本发明提供识别参与整联蛋白介导的信号传导的信号载体的方法，鉴定阻断整联蛋白介导信号传导的试剂的方法，使用阻断整合蛋白介导的信号传导调节生物和病理过程的试剂的方法，以及阻断整合素介导的信号传导的试剂。

    INHIBITORY IMMUNOGLOBULIN POLYPEPTIDES TO HUMAN PDGF BETA RECEPTOR
    4.
    发明申请
    INHIBITORY IMMUNOGLOBULIN POLYPEPTIDES TO HUMAN PDGF BETA RECEPTOR 审中-公开
    人PDGF受体抑制免疫球蛋白多肽

    公开(公告)号：WO1993010805A1

    公开(公告)日：1993-06-10

    申请号：PCT/US1992010359

    申请日：1992-12-01

    Applicant: COR THERAPEUTICS, INC. ,  RAMAKRISHNAN, Vanitha ,  ESCOBEDO, Maria, A. ,  FRETTO, Larry, J.

    Inventor： COR THERAPEUTICS, INC.

    IPC: A61K37/00

    CPC classification number: C07K16/2863 ,  A61K38/00 ,  C07K14/71 ,  C07K2317/34

    Abstract: The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indicated by inhibition of receptor phosphorylation and dimerisation, and by inhibition of PDGF-mediated mitogenesis, chemotaxis and migration of cells displaying the human PDGF type beta receptor on the cell surface. Nucleic acids encoding the immunoglobulin polypeptides are also included in the invention. The immunoglobulin polypeptides have diagnostic and therapeutic uses.

    Abstract translation: 本发明涉及特异性结合人β型PDGF受体的细胞外结构域的免疫球蛋白多肽。 免疫球蛋白多肽与受体的结合抑制PDGF诱导（或刺激的）受体活化，如通过受体磷酸化和二聚化的抑制以及通过抑制PDGF介导的有丝分裂，趋化性和显示人PDGF型β受体的细胞的迁移所表明的 在细胞表面。 编码免疫球蛋白多肽的核酸也包括在本发明中。 免疫球蛋白多肽具有诊断和治疗用途。

    RECOMBINANT AGENTS AFFECTING THROMBOSIS
    5.
    发明申请
    RECOMBINANT AGENTS AFFECTING THROMBOSIS 审中-公开
    影响血栓形成的重组药物

    公开(公告)号：WO1992004378A1

    公开(公告)日：1992-03-19

    申请号：PCT/US1991006337

    申请日：1991-09-04

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  WOLF, David

    IPC: C07K13/00

    CPC classification number: C12N9/647 ,  A61K38/00 ,  C07K14/745 ,  C12N9/6432 ,  C12Y304/21006

    Abstract: Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be conveniently prepared using recombinant techniques. In addition, modified forms of Factor Xa that generate Factor Xa in serum but have extended half-lives are useful in treating hemophilic conditions. These modified forms of Factor Xa are typically acylated forms of the serine residue in the active site which are slowly deacylated in vivo.

    IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION
    6.
    发明申请
    IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION 审中-公开
    Bap-1的鉴定，蛋白质在蛋白质整合和参与整合信号转导中的作用

    公开(公告)号：WO1998022583A1

    公开(公告)日：1998-05-28

    申请号：PCT/US1997020951

    申请日：1997-11-18

    Applicant: COR THERAPEUTICS, INC.

    Inventor： COR THERAPEUTICS, INC. ,  LI, Shengfeng ,  PHILLIPS, David, R.

    IPC: C12N15/12

    CPC classification number: C07K14/47 ,  A61K38/00

    Abstract: The present invention provides the amino acid and nucleotide sequence of a protein that binds to beta 3 integrins, alpha IIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling.

    Abstract translation: 本发明提供了结合β3整联蛋白，αIIb和Src激酶并参与整联蛋白介导的信号传导的蛋白质的氨基酸和核苷酸序列。 基于该公开内容，本发明提供了用于鉴定阻断整联蛋白介导的信号传导的试剂的方法，使用阻断整联蛋白介导的信号传导调节生物和病理过程的试剂的方法以及阻断整合素介导的信号传导的试剂。

    METHODS FOR PRODUCTION OF PURIFIED SOLUBLE TYPE B AND TYPE A HUMAN PLATELET-DERIVED GROWTH FACTOR RECEPTOR FRAGMENTS
    10.
    发明申请
    METHODS FOR PRODUCTION OF PURIFIED SOLUBLE TYPE B AND TYPE A HUMAN PLATELET-DERIVED GROWTH FACTOR RECEPTOR FRAGMENTS 审中-公开
    纯化溶剂型B和A型人类平板衍生生长因子受体片段的生产方法

    公开(公告)号：WO1993011223A1

    公开(公告)日：1993-06-10

    申请号：PCT/US1992010430

    申请日：1992-12-01

    Applicant: COR THERAPEUTICS, INC. ,  WOLF, David ,  TOMLINSON, James, E.

    Inventor： COR THERAPEUTICS, INC.

    IPC: C12N01/21

    CPC classification number: C07K14/71 ,  A61K38/00

    Abstract: Cell lines and methods for high efficiency production of soluble peptides having platelet-derived growth factor (PDGF) ligand binding activity. Cell lines are provided which secrete soluble fragments from extracellular regions of PDGF receptor (PDGF-R) polypeptides. Methods using these cell lines for production of the fragments are also provided.

    Abstract translation: 用于高效生产具有血小板衍生生长因子（PDGF）配体结合活性的可溶性肽的细胞系和方法。 提供从PDGF受体（PDGF-R）多肽细胞外区分泌可溶性片段的细胞系。 还提供了使用这些细胞系生产片段的方法。

Patent Agency Ranking